Medicine
Onyda XR 0.1 mg/mL extended-release oral suspension
Onyda XR 0.1 mg/mL extended-release oral suspension is a prescription medicine containing Clonidine for oral use, marketed by NextWave Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Clonidine
- Brand
- Onyda XR
- Strength
- 0.1 mg/mL
- Dosage form
- Extended-release oral suspension
- Route
- Oral
- Packs
- 30 mL
- Marketing authorisation holder
- NextWave Pharmaceuticals
- Manufacturer
- NextWave Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Store and dispense ONYDA XR in the original bottle.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C02AC01 Clonidine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 August 2024
- Identifiers
- RxCUI 2690727, 2690735DailyMed set ID 4a15c850-9da5-4bdc-a34d-7f740a6149b7NDC 24478-148Application NDA217645
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 mL in 1 bottle | 24478-148-03 | NextWave Pharmaceuticals | 13 August 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 3 September 1974 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Clonidine
Clinical summary
Clonidine is a central alpha-2 adrenergic agonist indicated in the treatment of hypertension. It is available as tablets, transdermal patches and extended-release tablets for oral and epidural use. MedsAcross supplies Clonidine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ClonidineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Clonidine Transdermal System USP, 0.1 mg/day prescribing information (TruPharma) · U.S. National Library of Medicine, DailyMed
Need Onyda XR 0.1 mg/mL extended-release oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.